Member Info for Kiwi_

Delayed Buys 300K and 147K

Just out by Zak Mir

https://www.share-talk.com/share-talk-bulletin-board-heroes-friday-12th-july-2019/?utm_source=twitter&utm_medium&utm_campaign

langtro, call it what you like mate. People have been saying that since 2p, I can't see the share price sitting at 6p on FDA approval. Did you read the Presidential order?

https://www.whitehouse.gov/presidential-actions/executive-order-advancing-american-kidney-health/?utm_source=twitter

Look at that they drop it and go fill or kill to buy again!

drax, each to their own mate. But you seen how difficult it is to buy here even on a quiet day

With such a low market cap here with all the products available it shows how easy we could get taken out.

Degsy, that is a good comparison

LB28 I wouldn't rule it out, we still have loads that obviously complements this

lowlife, when you look at the stats it is hard to say. IMHO the market cap could double from here, current mc is only a tiny £7 million

and the link:

https://www.researchgate.net/publication/224005176_Prevalence_of_Kidney_Stones_in_the_United_States

Another set of survey results

The cross-sectional survey design limits causal inference regarding potential risk factors for kidney stones. Kidney stones affect approximately 1 in 11 people in the United States. These data represent a marked increase in stone disease compared with the NHANES III cohort, particularly in black, non-Hispanic and Hispanic individuals. Diet and lifestyle factors likely play an important role in the changing epidemiology of kidney stones.

Degsy, that strengthens the case further on why the FDA should approve this

and this is from the year 2000

Prevalence of Kidney Stones

The lifetime incidence of kidney stones is nearly 13 percent in men and 7 percent in women. Once an individual has formed a stone, the likelihood of recurrence is 50 percent or greater at five years and up to 80 percent at 10 years.

Inpatient hospital stays: For the year 2000 it is estimated that 177,496 adults 20 years or older were admitted to the hospital with "calculus of kidney and ureters" as a primary diagnosis.
Physician office and hospital outpatient visits combined: For the year 2000 there were approximately 2,000,000 visits by adults 20 years and older with "calculus of kidney and ureters" as a listed diagnosis. In the same year there were approximately 2,700,000 visits by adults 20 years and older with "urolithasis listed as diagnosis.
Cost: $2.07 billion was expended for evaluation and treatment in the year 2000.

Source: National Kidney and Urologic Diseases Information Clearinghouse

Fill or kill only on no trades and it only just ticked up to 6.1p

Breaking out!

Broker now phone only and wants 6.p to buy, current ask 5.9

We may see an RNS off of the back of that Degsy given RENYX RNSsd it

Here is the link:

https://www.uwhealth.org/urology/how-common-are-kidney-stones/11208

Agreed Degsy! I think that sub 15 million market cap pre FDA won't be around for much longer

You finally bought in Wilfred? ;) What price did you get mate?